Krensavage Asset Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001609251

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 18 positions · Total reported value $263.22M · Top-10 concentration 89.4% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 20.0% · 0 new · 2 cut · 2 exited

Active Share (vs S&P 500): 99.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +6.8% · vs SPY -8.0% · Prev Value $255.70M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Krensavage Asset Management, LLC disclosed 18 equity positions with a combined reported value of $263.22M. The filing implies a focused portfolio: its ten largest positions account for 89.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ENTA ($41.79M), JAZZ ($40.44M), UTHR ($37.54M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Krensavage Asset Management, LLC opened 0 new positions, trimmed 2 and fully exited 2, a turnover rate of 20.0% of positions. The portfolio's overlap with the prior quarter was 90% of names.

Of the 2 positions fully exited versus the prior quarter, the largest were INDV ($10.35M), ALKS ($3.81M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

No new positions this quarter.

Fully Exited (vs previous quarter)

  • INDV INDIVIOR PHARMACEUTICALS INC · prev qtr: $10.35M
  • ALKS ALKERMES PLC · prev qtr: $3.81M

Insider Transactions (Form 4)

Latest Krensavage Asset Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Krensavage Asset Management, LLC, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 18 positions worth $263.22M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-78631 (status: Approved), registered 2013-10-04
  • Regulatory AUM (Form ADV): $300.23M as of 2026-03-25
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 18 positions · $263.22M reported value (Q2 2026)
  • Top 10 holdings = 89.4% of reported value
  • Largest position: ENTA (ENANTA PHARMACEUTICALS INC COM) at 15.9%
  • Average position size: $14.62M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 added, 2 reduced, 2 exited
  • 12 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund seems to maintain a cautiously optimistic stance, with a focus on healthcare companies that have stable positions and potential growth prospects. The slight reduction in some holdings suggests a preference for maintaining existing positions rather than seeking significant shifts. 2. Key Moves: - Added: Abbott Laboratories (ABBV) was significantly added to the portfolio, which could indicate a belief in the company's potential growth or a shift in sector preference. - Reduced: Exelixis (EXEL) and United Therapeutics (UTHR) saw reductions in share count, potentially reflecting concerns about growth prospects or risk profiles. - No Change: Most holdings remained steady in terms of share count and weighting. 3. Portfolio Structure: - Passive/Active: The portfolio seems to lean towards passive management, with few new additions and no major changes in strategy. - Sector Bias: Strong bias towards healthcare, particularly biotech and pharmaceutical companies. - Risk Appetite: Moderate risk appetite, with a focus on stable, established companies and no new positions added, suggesting a preference for lower-risk investments. 4. Per-Holding One-Liner: - ENTA: Biotechnology company focused on developing therapies for viral diseases. - JAZZ: Biopharmaceutical company focusing on therapies for rare genetic disorders. - UTHR: Biotechnology company specializing in treatments for pulmonary hypertension. - BMRN: Biotechnology company focusing on treatments for rare genetic diseases. - EXEL: Biotechnology company working on cancer and immunology therapies. - ABBV: Multinational healthcare company with a diverse portfolio of pharmaceuticals and medical devices. - SNY: Global pharmaceutical company known for a wide range of treatments in various therapeutic areas. - SUPN: Biotechnology company focusing on treatments for central nervous system disorders. - RARE: Biotechnology company specializing in treatments for ultra-rare genetic diseases. - VNDA: Biotechnology company working on therapies for orphan diseases. 5. One-Sentence Style Summary: Krensavage Asset Management's Q2 2026 rebalancing indicates a conservative approach, maintaining a focus on established healthcare companies with potential for growth, while selectively adding exposure to Abbott Laboratories.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.87M $41.79M 15.88%
15.88%
Hold
2 167.82K $40.44M 15.36%
15.36%
Hold
3 69.28K $37.54M 14.26%
14.26%
Reduce
4 524.79K $30.03M 11.41%
11.41%
Hold
5 370.69K $20.17M 7.66%
7.66%
Reduce
6 200.00K $18.15M 6.89%
6.89%
Add
7 323.95K $13.82M 5.25%
5.25%
Hold
8 280.68K $13.05M 4.96%
4.96%
Hold
9 390.88K $13.05M 4.96%
4.96%
Hold
10 1.18M $7.22M 2.74%
2.74%
Hold
11 59.52K $5.54M 2.10%
2.10%
Hold
12 96.73K $5.07M 1.93%
1.93%
Hold
13 20.00K $4.32M 1.64%
1.64%
Hold
14 6.00K $3.74M 1.42%
1.42%
Add
15 1.14M $3.70M 1.41%
1.41%
Add
16 534.52K $2.73M 1.04%
1.04%
Add
17 120.94K $1.77M 0.67%
0.67%
Hold
18 157.99K $1.10M 0.42%
0.42%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 88% · recall 88% · F1 88% · avg rank error 1.4 · Top-10 turnover 13%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% EXEL · UTHR · REGN · BIIB · CAH · TARO · ALKS · JAZZ · SNY · ENTA EXEL · UTHR · BIIB · TARO · CAH · ENTA · JAZZ · REGN · BNTX · SNY
2024-Q2 100% 100% 100% EXEL · UTHR · BIIB · TARO · CAH · ENTA · JAZZ · REGN · BNTX · SNY EXEL · UTHR · BIIB · TARO · CAH · ENTA · JAZZ · BNTX · REGN · SNY
2024-Q3 80% 80% 80% EXEL · UTHR · TARO · BIIB · CAH · ENTA · JAZZ · BNTX · SNY · REGN UTHR · EXEL · CAH · BIIB · ENTA · JAZZ · BNTX · SNY · ALKS · INDV
2024-Q4 100% 100% 100% UTHR · EXEL · CAH · BIIB · ENTA · JAZZ · BNTX · SNY · ALKS · INDV UTHR · EXEL · CAH · BIIB · JAZZ · ENTA · INDV · BNTX · SNY · ALKS
2025-Q1 80% 80% 80% UTHR · EXEL · CAH · BIIB · ENTA · JAZZ · INDV · BNTX · SNY · ALKS EXEL · UTHR · CAH · SUPN · JAZZ · ENTA · GSK · INDV · SNY · BNTX
2025-Q2 90% 90% 90% EXEL · UTHR · CAH · SUPN · JAZZ · ENTA · GSK · INDV · SNY · BNTX UTHR · CAH · EXEL · JAZZ · ENTA · SUPN · INDV · GSK · AVDL · BNTX
2025-Q3 80% 80% 80% UTHR · CAH · EXEL · JAZZ · ENTA · SUPN · INDV · GSK · AVDL · BNTX UTHR · ENTA · JAZZ · BMRN · EXEL · SUPN · SNY · AVDL · GSK · CAH
2025-Q4 90% 90% 90% UTHR · ENTA · JAZZ · BMRN · EXEL · SNY · SUPN · AVDL · GSK · CAH UTHR · ENTA · BMRN · JAZZ · EXEL · AVDL · SNY · SUPN · CAH · INDV
2026-Q1 80% 80% 80% ENTA · UTHR · BMRN · JAZZ · EXEL · AVDL · SNY · SUPN · CAH · INDV UTHR · ENTA · JAZZ · BMRN · EXEL · SNY · SUPN · INDV · RARE · VNDA
2026-Q2 ★ 90% 90% 90% UTHR · ENTA · JAZZ · BMRN · EXEL · SNY · SUPN · INDV · RARE · VNDA ENTA · JAZZ · UTHR · BMRN · EXEL · ABT · SNY · SUPN · RARE · VNDA

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Krensavage Asset Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Krensavage Asset Management, LLC reported 18 equity positions worth $263.22M in aggregate; its largest disclosed positions were ENTA ($41.79M), JAZZ ($40.44M), UTHR ($37.54M).

How large is Krensavage Asset Management, LLC's portfolio?

Krensavage Asset Management, LLC reported $263.22M of long equity holdings across 18 positions as of 2026-Q2. Top-10 holdings account for 89.4% of reported value.

What is Krensavage Asset Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/krensavage-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →